ARFGAP1 Double Nickase Plasmid (h2): sc-403939-NIC-2
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- ARFGAP1 Double Nickase Plasmid (h2) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- ARFGAP1 Double Nickase Plasmid (h2) and ARFGAP1 Double Nickase Plasmid (h22) encode distinct paired gRNA designs targeting ARFGAP1. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: ARFGAP1 Antibody (C-4): sc-271303
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
ARFGAP1 Double Nickase Plasmid (h2) | sc-403939-NIC-2 | 20 µg | $410.00 |
Human ARFGAP1 encodes ADP-ribosylation factor GTPase-activating protein 1, a Golgi-associated regulator that accelerates GTP hydrolysis on ARF family small GTPases to coordinate vesicle budding and coat dynamics. By modulating COPI-dependent retrograde trafficking and endosome–Golgi transport, ARFGAP1 contributes to membrane curvature, cargo sorting, and maintenance of Golgi architecture, linking ARF signaling to broader secretory and recycling pathways. Dysregulation of ARFGAP1-mediated trafficking has been investigated in contexts where proteostasis and organelle transport are perturbed, including neurodegeneration-related mechanisms involving vesicular transport and protein handling. Gene editing of ARFGAP1 enables mechanistic studies of ARF pathway control, vesicle biogenesis, and Golgi function using knockout/knock-in models, interaction mapping, and trafficking assays in human cell systems.
ARFGAP1 Double Nickase Plasmid (h2) consists of a matched pair of plasmids engineered for high-specificity editing of the ARFGAP1 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within ARFGAP1. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt ARFGAP1 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of ARFGAP1-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.